Aviant

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aviant

Aviant is a medicinal preparation whose active component is Desloratadine, a synthetic compound classified as a second-generation antihistamine used to manage symptoms arising from allergic responses. As a single-ingredient product, its purpose is centered entirely on providing systemic anti-allergic effects by blocking the action of histamine in the body. The medication is available for oral administration.


Quick Facts

Property Description
Active Ingredient Desloratadine (INN)
Form Film-coated tablet, Oral solution
Pharmacological Class Second-generation H1 Antihistamine
Origin Synthetic (Active metabolite of Loratadine)
General Purpose Provides systemic anti-allergic relief

What Type of Medicine is Aviant and What is its Composition?

Aviant's active ingredient is Desloratadine (INN), a synthetic substance that belongs to the antihistamine pharmacological class. This formulation is notable because Desloratadine is the active metabolite of Loratadine. As the active form of the substance, Desloratadine exerts the desired therapeutic action. This status is clinically recognized for promoting a faster onset of action compared to its precursor. The medication is offered as a single-ingredient preparation, contained either in a solid film-coated tablet or a liquid oral solution with standard pharmaceutical excipients.

How is Aviant Pharmacologically Classified?

Aviant is classified as a second-generation antihistamine, specifically a tricyclic H1 receptor antagonist. This modern classification is critical because it indicates the substance has enhanced selectivity for peripheral H1 receptors found outside the central nervous system. Desloratadine functions as an H1 receptor antagonist, which allows the medicine to interrupt the body's allergic response mechanisms. The functional profile is defined as non-sedating, a key differentiating factor that makes it suitable for individuals needing anti-allergic relief while maintaining alertness throughout the day.

What is the General Purpose of Aviant?

The primary general purpose of Aviant is to provide systemic anti-allergic effects through selective histamine blocking. The drug acts by binding to and blocking the H1 receptors, thereby preventing the chemical histamine—a primary mediator of allergic reactions—from initiating its effects. By interrupting this fundamental biological process, the medicine helps to mitigate the body's overreaction to allergens, with the added benefit of possessing documented anti-inflammatory properties. A typical use scenario involves providing sustained relief to a patient experiencing seasonal allergic symptoms.

Regulatory References

  1. Aerius (Desloratadine) EPAR

What side effects are possible with Aviant?

Possible Side Effects and Safety Information

Official regulatory documents detail the safety profile of Aviant (abiraterone acetate), including adverse reactions classified by frequency and body system. The primary risks requiring specific management are related to Mineralocorticoid Excess and Hepatotoxicity.


Adverse Reactions by Frequency and System

Classification Examples of Adverse Reactions (by System)
Very Common (ge 1/10) Hypertension, Hypokalaemia (low potassium), Peripheral Oedema (fluid retention), Diarrhoea, Urinary Tract Infection.
Common (ge 1/100 to < 1/10) Cardiac Failure, Angina Pectoris, Arrhythmia, Fractures, Alanine Aminotransferase increased, Aspartate Aminotransferase increased, Rash.
Uncommon (ge 1/1,000 to < 1/100) Adrenal Insufficiency, Myopathy, Rhabdomyolysis.
Rare (< 1/1,000) Allergic Alveolitis.

Serious adverse reactions documented in regulatory sources include severe Hepatic Toxicities, such as acute liver failure and fulminant hepatitis, as well as Cardiac Failure and Rhabdomyolysis.


Safety Restrictions and Monitoring Notes

The medicine is contraindicated in two key populations: women who are or may potentially be pregnant and patients with severe hepatic impairment (Child-Pugh Class C). Caution is advised in patients with a history of cardiovascular disease, and the safety has not been established in patients with a baseline Left Ventricular Ejection Fraction (LVEF) of less than 50% or New York Heart Association (NYHA) Class III or IV heart failure.

Mandatory monitoring of blood pressure, serum potassium, and symptoms of fluid retention is required at least monthly. Additionally, liver enzyme levels (serum transaminases and bilirubin) must be measured prior to starting treatment, frequently for the first three months, and monthly thereafter. The medicine is not recommended for use in combination with Radium Ra 223 dichloride due to an increased risk of bone fracture and death.


Regulatory Safety Summary

The official safety information structures the risk profile by requiring active management of Mineralocorticoid Excess symptoms and frequent, mandatory monitoring for Hepatotoxicity. The contraindications and restrictions define specific patient populations and co-administered treatments that must be avoided, ensuring the risk assessment is clearly established.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation requires individuals to seek immediate medical attention if an overdose of Aviant (Desloratadine) is suspected. The overdose profile is primarily described as an exaggeration of known adverse effects, which may present as a higher magnitude of effects such as somnolence (sleepiness), headache, or fatigue.


Documented Overdose Manifestations

Overdose Presentation Regulatory Notes
Central Nervous System Symptoms may include somnolence; seizures have been reported in post-marketing cases.
Cardiovascular System Post-marketing surveillance includes reports of tachycardia (fast heart rate).

Management guidelines in regulatory documents state that symptomatic and supportive treatment is recommended. It is officially noted that no specific antidote is known for Desloratadine. Physicians should consider standard procedures to remove the unabsorbed substance, although the substance is documented as not eliminated by haemodialysis.

Population-Specific Consideration: Special attention is warranted for the pediatric population, where post-marketing reports have included more severe outcomes, such as arrhythmia, bradycardia (slow heart rate), and QT prolongation.

Therapeutic Uses of Aviant

What Aviant Treats: Main Uses and Benefits

Easing Periods of Acute Symptomatic Discomfort

Aviant is commonly used to help with situations involving certain distressing symptoms that may appear suddenly or intensify quickly. It is considered relevant in contexts marked by increased discomfort or tension. It is often used when symptoms create noticeable physiological strain, and may be part of symptomatic management when short-term symptomatic assistance is needed. The medicine may assist with managing symptoms and is commonly used when short-term symptomatic assistance is needed.

Supporting Daily Functional Stability

This medicine is applied across domains where additional symptomatic support is needed, relevant in conditions where functional stability becomes affected. It is used across conditions characterized by periods of heightened symptoms and fluctuating manifestations. Aviant may help patients cope more steadily with symptom fluctuations, and supports general well-being during symptomatic phases.

Relief from Heightened Physiological Tension

Aviant is relevant in areas where short-term symptom management is appropriate, particularly when symptoms intensify. It may assist with managing symptoms linked to heightened physiological activity or increased systemic burden. It contributes to easing the overall symptom load and supports general well-being during symptomatic phases.


Key Therapeutic Areas for Aviant

Aviant is primarily used in situations involving distressing symptoms, including those related to physical discomfort, systemic imbalance, and heightened physiological activity. It is commonly applied in scenarios where additional management of discomfort is required, offering symptomatic support during acute or disruptive episodes and periods of increased physiological stress.

“It is used in areas where short-term symptom management is appropriate.”

Quick Fact: Relief for Episodic Distress
Aviant is relevant in contexts involving heightened systemic burden or when symptoms create noticeable functional strain.

Regulatory References

  1. NIH MedlinePlus overview of Palliative Care

Eligibility and Restrictions for Use

Official Eligibility Profile for Aviant (Desloratadine)

The official eligibility profile for Aviant strictly defines the population groups permitted or prohibited from using the medicine, based solely on regulatory documentation (e.g., FDA, EMA SmPC).


Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed (as stated in label) Adults and Adolescents (12 years of age and older). Children aged 6 months and older are eligible for use with specific liquid or lower-strength formulations.
Populations for whom use is not recommended (if applicable) Breastfeeding women are officially not recommended to use the medicine as desloratadine is excreted into human milk.
Populations for whom use is contraindicated Patients with known hypersensitivity to the active substance Desloratadine, any of the product's excipients, or to Loratadine.
Age-related eligibility rules Infants below 6 months of age: Safety and effectiveness have not been established. Children below 12 years of age: The 5 mg film-coated tablet formulation is not established for use.
Condition-specific eligibility rules Hepatic Impairment or Renal Impairment requires a dosage adjustment for restricted use and caution in severe cases.
Pregnancy and lactation eligibility status (if explicitly documented) Pregnancy: It is preferable to avoid the use as a precautionary measure. Lactation: Use is not recommended.
Eligibility-related restrictions Patients with excipient intolerances such as galactose intolerance should not take the film-coated tablet formulation.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification/Basis
Eligibility severity classification (as defined in official documents) Contraindicated (Absolute Prohibition), Not Recommended (Avoidance), Conditional Use (Organ Impairment), Not Established (Insufficient Data).
Regulatory basis (EMA / FDA / etc.) Based on official governmental Prescribing Information and Summary of Product Characteristics (SmPC).
Eligibility-context constraints (as defined in official documents) Constraints are based on Age Thresholds, Known Hypersensitivity, Organ Clearance Function, and Reproductive Status.

Resulting Eligibility Structure

Official Eligibility Statements:

  • Hypersensitivity to Desloratadine or Loratadine is listed as an absolute contraindication.
  • Use is not established in infants below 6 months of age.
  • Renal and Hepatic Impairment necessitate a dosage adjustment for restricted use.
  • Use is officially not recommended in breastfeeding women.
  • Caution is advised in patients with a history of seizures.

Connection to the overall eligibility profile

Regulatory documents define eligibility by establishing formal contraindications for hypersensitivity, setting age limits where safety is not established, and applying mandatory conditional use status for adult patients with impaired hepatic or renal function. The profile is further constrained by excipient warnings and the official status of non-recommendation during breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Aviant (Desloratadine) is structured around documented pharmacokinetic outcomes with co-administered substances. The primary finding is that co-administration with certain prescription medicines results in elevated plasma concentrations of Desloratadine and its active metabolite (3-hydroxydesloratadine).


Documented Pharmacokinetic Interactions

The following substances have been formally cited in regulatory documents as altering Desloratadine exposure:

Substance Category Specific Examples Documented Outcome
Antifungals & Antibiotics Ketoconazole, Erythromycin, Azithromycin Increased Cmax and AUC of Desloratadine.
H2 Antagonists & SSRIs Cimetidine, Fluoxetine Increased Cmax and AUC of Desloratadine.

Despite the elevated exposure, clinical studies found these pharmacokinetic interactions were not associated with clinically significant changes in the safety profile or electrocardiographic parameters. No mandatory time separation rules are documented for co-administration.

Interactions with Other Products and Conditions

Desloratadine's bioavailability is not significantly affected by co-administration with food or grapefruit juice. Regarding alcohol, clinical trials showed no potentiation of performance impairment. However, regulatory caution is advised based on post-marketing reports of alcohol intolerance and intoxication. Exposure is also documented to be significantly higher in certain populations, including individuals identified as slow metabolizers and those with severe renal or hepatic impairment.

Mechanism of Action

Positive Allosteric Modulation: The Core Mechanism

Aviant acts through positive allosteric modulation (PAM) of GABA-A receptors. This mechanism involves increasing the efficacy of the receptor's function by amplifying the effect of the endogenous ligand, GABA, thereby increasing neuronal hyperpolarization throughout the central nervous system.


Central Nervous System (CNS) Inhibitory Cascade

Aviant's activity initiates a rapid cascade where increased chloride ion ( Cl^-) influx hyperpolarizes the postsynaptic neuron, actively opposing its excitation. This fundamental inhibitory mechanism is relevant in neural circuits prone to heightened activity, such as those involved in regulating arousal and efferent motor signaling.


Influencing Arousal and Motor Tone Circuits

The resulting systemic inhibition influences neural circuits that govern arousal and skeletal muscle activity. This modulation contributes to physiological adjustments that include decreased vigilance, reduced neural excitability, and decreased motor tone, which are the direct physiological consequences of the enhanced central inhibitory action.

Dosage and Administration Information

Official Administration and Regimen

Aviant (desloratadine) is administered strictly via the oral route and is available in formulations including a film-coated tablet, an oral solution, and an orally disintegrating tablet (ODT). The standard adult dosing regimen for individuals 12 years of age and older is 5 mg taken once daily. This once-daily frequency is maintained for all approved age groups, and the medicine may be taken without regard to meals, which simplifies the timing of administration.

Form-Specific Instructions

Specific administration procedures apply to certain dosage forms. If utilizing the oral solution, the dose must be measured precisely using a calibrated measuring device to ensure accurate delivery. For the orally disintegrating tablets, the unit must be removed immediately after opening the blister and allowed to dissolve on the tongue before swallowing with saliva, with or without water.

Duration and Population Adjustments

Treatment duration is structured by the pattern of symptoms. For intermittent allergic symptoms (present for <4 days/week or <4 weeks), the medicine can be discontinued upon symptom resolution and reinitiated upon recurrence. For persistent symptoms, continued treatment may be proposed. A critical adjustment rule applies to adults with renal or hepatic impairment, for whom the starting dose is modified to 5 mg every other day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aviant

The available evidence for Aviant (Desloratadine) is drawn from formal clinical research that was used in research exploring how symptoms change over time related to allergic conditions. Studies were conducted to characterize changes in symptoms across its two main areas of use. Findings describe group patterns in observed populations, but research does not determine whether an individual will respond similarly.


Evidence for Use in Allergic Rhinitis (Hay Fever) Studies

Research has been applied in studies examining patient-reported experiences of fluctuating symptoms, aiming to characterize the effects of the active substance during periods of heightened symptom activity. The core evidence consists of short-term, double-blind randomized controlled trials (RCTs). These studies examined outcomes related to physical discomfort, primarily by measuring the Total Symptom Score (TSS), which is a composite score for nasal and ocular symptoms. Findings describe patterns observed in the studies where participants reported changes measured in their total symptom scores compared to the placebo groups over the study period (typically 2–4 weeks).

Evidence for Use in Chronic Urticaria (Hives) Studies

Studies for chronic idiopathic urticaria (hives) typically involve randomized, placebo-controlled trials lasting approximately six weeks. Researchers was studied for outcomes related to systemic or functional imbalance, with a strong focus on patient-reported outcomes describing perceived discomfort related to itching and hive activity. Studies report how symptoms evolved in the observed populations, showing changes measured in patient-reported itching and hive scores during the trial period compared to placebo.

Duration of Evidence and Specific Patient Groups

The main body of evidence is derived from trials with relatively limited follow-up durations (2 to 6 weeks). While regulatory reviews acknowledge that long-term use appears to be generally consistent with the short-term profile, controlled trial data extending to one year or more are limited. Research has been studied for children as young as 6 months and adolescents, comparing outcomes related to symptom intensity or variability to the findings in adult data. However, subgroup findings are uncertain in the context of rare comorbidities, and results apply only to the populations studied.

Key Studies & References

  1. Efficacy and Safety of Desloratadine in Chronic Urticaria: A Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Aviant (FAQ)

Q: How quickly does Aviant start working after taking it?

Official regulatory information indicates that the concentration of the medicine in the blood reaches its peak level, known as Cmax, at approximately 3 hours after a single oral dose. This timeframe suggests when the drug’s concentration is highest in the bloodstream.


Q: How long do I usually have to take Aviant for?

The required duration depends on your symptoms. For intermittent (occasional) symptoms, the medicine may be stopped when symptoms resolve and restarted if they reappear. For persistent (long-lasting) symptoms, continuous treatment is an option that may be discussed with a healthcare provider, according to official product information.


Q: Will Aviant make me feel drowsy or affect my ability to drive?

Aviant is classified as a non-sedating antihistamine, meaning it is not expected to cause sleepiness in most people. However, post-marketing reports indicate some patients have experienced sleepiness or dizziness. Patients are generally advised to observe their response to the medicine before engaging in activities that require full alertness, such as driving or operating machinery.


Q: Are there any specific foods or drinks I should avoid while on Aviant?

Official studies show that the medicine’s effectiveness is not affected by food or grapefruit juice. However, regulatory caution is advised regarding the use of alcohol due to post-marketing reports of potential alcohol intolerance or intoxication. Consultation with a healthcare provider can clarify any specific restrictions related to food or drink.


Q: Is it normal to feel a mild headache when first starting Aviant?

Regulatory documents indicate that headache was one of the adverse events reported in clinical trials. Headaches were among the most frequent side effects reported in the official safety summaries for the medicine.


Q: What does the research say about the long-term safety of Aviant?

The main body of evidence supporting the use of Aviant comes from controlled clinical trials with relatively limited follow-up durations, typically ranging from 2 to 6 weeks. While long-term use is generally considered consistent with the short-term profile, controlled trial data extending beyond one year are limited.


Q: How is Aviant different from older medicines used for the same purpose?

Aviant is classified as a second-generation H1 antihistamine. Unlike older antihistamines, it is more selective and is considered non-sedating because it is less likely to cause sleepiness. It is also the active form (metabolite) of another commonly used antihistamine.


Q: Why do some people need to take Aviant for a short time and others for longer?

The duration is determined by the pattern of symptoms, according to official guidance. If symptoms are intermittent (less than 4 days per week or less than 4 weeks), the medicine is taken only as needed. If symptoms are persistent (4 days or more per week and more than 4 weeks), continuous treatment is an option that may be discussed with a healthcare provider.


Q: What is the typical time frame to see the full benefits of Aviant?

Clinical trials for allergic rhinitis symptoms often measure effectiveness over a period of 2 to 4 weeks. Studies for chronic hives typically lasted around 6 weeks. These periods represent the observation times used by researchers to characterize changes in patient symptoms.


Q: Can Aviant be crushed or split if it's a tablet?

The administration instructions for the standard film-coated tablet do not mention crushing or splitting it. The film-coated tablet formulation is intended to be swallowed whole. A separate orally disintegrating tablet (ODT) formulation is available that is specifically designed to dissolve on the tongue before swallowing.


Q: Does Aviant cause weight gain or loss?

Weight change is not listed as a common or very common side effect in the main safety tables of the official regulatory information. However, post-marketing data compiled from regulatory sources has sometimes reported weight gain under the 'Metabolic' adverse reaction classification.


Q: Does Aviant interfere with sleep?

The medicine is classified as a non-sedating agent. Despite this, regulatory-derived data has reported adverse events such as insomnia (difficulty sleeping) and sleepiness (somnolence) in some clinical trials.


Q: What percentage of people experience the most common side effect of Aviant?

The most common side effect for patients 12 and older is headache, which was reported in up to 14% of patients in some clinical trials. Other common reactions in different age groups include upper respiratory tract infections and diarrhea, with rates up to 21.2% and 19.7% in infants, respectively.


Q: Are there different strengths or formulations of Aviant available?

Yes, official product information confirms that Aviant is available in several formulations, including a film-coated tablet, an oral solution (liquid), and an orally disintegrating tablet (ODT). Different strengths are often available to treat children and infants.


Q: What are the most common side effects of Aviant that people experience?

According to official compilations of safety data, the most common side effects reported for patients 12 years and older include headache, followed by fatigue, dizziness, and nausea.


Q: Can I use alcohol while taking a course of Aviant?

Clinical studies found no increase in performance impairment when the medicine was co-administered with alcohol. However, regulatory authorities still advise caution, as post-marketing reports have documented instances of alcohol intolerance or intoxication.


Q: What happens if I miss a dose of Aviant?

Official patient information generally outlines a procedure for a missed dose, such as taking the dose when remembered unless it is close to the time for the next dose. However, you should refer to the specific guidance provided by your prescribing professional. It is important to inform a healthcare provider about all medications being taken to check for potential interactions.


Q: Does Aviant have any known interactions with herbal supplements?

Specific interactions with herbal supplements are not always listed in regulatory documents. Healthcare professionals advise informing them about all products, including herbal supplements, to check for potential interactions.


Q: Can Aviant cause skin sensitivity to the sun?

Regulatory safety information compiled from post-marketing surveillance reports has documented instances of photosensitivity, which means increased sensitivity to sunlight. Consultation with a healthcare provider is recommended for guidance on sun exposure while using this medicine.


Q: Why is Aviant generally considered a 'first-line' treatment for its main use?

The medicine is often categorized as a preferred treatment because it is a second-generation antihistamine. This newer class is generally considered to have a more favorable profile due to its targeted action and the fact that it is non-sedating compared to older antihistamines.


Q: What are the signs that Aviant might not be working for me?

Official patient information advises that if symptoms do not improve or if they worsen after starting the medication, a consultation with a healthcare provider may be necessary. This is a general indicator that the treatment may need review.


Q: How long does Aviant stay in your system after you stop taking it?

The medicine has an elimination half-life of approximately 27 hours in healthy individuals. The half-life is the time it takes for the concentration of the medicine in the body to be reduced by half.


Q: Is there a patient support program or website for Aviant?

The medicine may be covered by patient assistance programs offered by its manufacturers. These programs are designed for individuals with financial hardship, and details about eligibility and application instructions are typically found on the manufacturer's official program website.


Q: Is Aviant a controlled substance or addictive?

Official regulatory documents do not classify this medicine as a controlled substance. Additionally, the official product labeling does not include warnings related to the risk of abuse, dependence, or addiction.


Q: Are there any food interactions that make Aviant less effective?

Official studies indicate that the medicine's absorption and bioavailability are not significantly affected by co-administration with food or grapefruit juice. This confirms that its effectiveness is maintained when taken with or without these products.


Q: Is Aviant an old or a relatively new medication?

Aviant (desloratadine) is classified as a second-generation antihistamine. It was initially approved in the U.S. in 2001.


Q: Can Aviant be used to prevent a condition, or to treat an active one?

The medicine is primarily approved to provide relief and treatment for the active symptoms of allergic rhinitis and chronic hives. In chronic (persistent) conditions, it may be taken continuously to manage symptoms over time.


Q: Why do some forums say Aviant has an 'off-label' use, even though the official text doesn't mention it?

Official regulatory documents only contain the uses that have been specifically approved by government agencies. Healthcare providers may sometimes use the medicine for other indications, which are considered 'off-label' and are not included in the official prescribing information.

How should Aviant be stored and disposed of?

How to Store and Dispose of Aviant?

This section outlines the official, mandatory requirements for storing and disposing of Aviant (Desloratadine), as documented in governmental regulatory labeling.

Mandatory Storage Requirements

To preserve the product's stability and systemic anti-allergic effects, the following rules must be followed:

  • Temperature and Environment: The medicine must be stored at a temperature not exceeding 30, C and must be protected from both moisture and light. Liquid formulations must also be kept from freezing.
  • Packaging: Store Aviant in its original package to ensure protection from moisture and maintain product integrity.
  • Child Safety: It is a mandatory requirement to keep out of the sight and reach of children.

Official Disposal Protocol

Official disposal instructions are based on governmental guidance for unused or expired medication:

  • General Rule: Unused product or waste material must be disposed of in accordance with local requirements.
  • Prohibition: Do not dispose of the medicine by throwing it into wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Aviant found in:

A-Z Index: